Wednesday, 25 Apr 2018

You are here

Mayo and UAB Awarded $1 million Grant for Patient Research

CreakyJoints and Pfizer have selected the Mayo Clinic and the University of Alabama at Birmingham (UAB) to each receive a $500K research award (funded by Pfizer Independent Grants) for Learning & Change.

Grants submitted from both centers haved focused on shared decision making between rheumatoid arthritis (RA) and health care providers.

The Mayo Clinic (Rochester, MN), lead by John M. Davis, III, MD, as the principal investigator,  for the first project titled, “The Impact of Arthritis Power on Rheumatoid Arthritis Shared Decision Making.” The objective is to improve shared decision making about treatment options and thereby enhance disease outcomes and health-related quality of life for RA patients. Data will be collected using the Creaky Joints "ArthritisPower" mobile application.

The UAB project, lead by principal investigator Huifeng Yun, PhD, is titled, “Integration of Patient Reported Outcomes (PROs) and Electronic Health Records (EHR) to Improve Shared Decision Making in Rheumatoid Arthritis.” This study will integrate individual patient reported outcomes (PRO) data collected from ArthritisPower with clinical and laboratory data from Electronic Health Records (EHR).

“We created ArthritisPower because we believe that patients should always be at the center of RA treatment decision-making. These projects rely on information coming directly from patients outside of the clinical setting to take into account patient preferences about medication efficacy and risks, and quality of life indicators that are important to people living with arthritis,” stated Seth Ginsberg, President and Co-Founder of Global Healthy Living Foundation and CreakyJoints. “We’re thrilled that Mayo and UAB will use ArthritisPower to inform their studies and add to our understanding of how arthritis patients think about their symptoms and treatment, and also how they use technology to communicate this information to their health care providers.”

ArthritisPower was created by CreakyJoints and supported by the Patient-Centered Outcomes Research Institute (PCORI). ArthritisPower is a patient-centered research registry for joint, bone, and inflammatory skin conditions. To learn more and join ArthritisPower, visit www.ArthritisPower.org.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Review: Take Two for Baricitinib

FDA staff remain worried about the safety of baricitinib, an oral JAK inhibitor intended for treatment of rheumatoid arthritis, according to briefing documents prepared for an advisory committee meeting on Monday.

Shared Epitope - Smoking Pathogenic Link Clarified

Proceedings of the National Academy of Sciences (PNAS) has published new research on the mechanistic link between the rheumatoid arthritis (RA) "shared epitope" (SE) risk alleles and environmental triggers such as cigarette smoke that leads to joint inflammation and bony destruction. 

Kineret Approved for Still's Disease in EU

SOBI has announced that Kineret (anakinra) has been approved by the European Commission (EC) for the treatment of Still’s disease (Systemic Juvenile Idiopathic Arthritis [SJIA] and Adult-Onset Still’s Disease [AOSD]), in all 28 European Union (EU) member states. Still's disease is a rare systemic multi-organ disorder of auto-inflammatory nature that affects approximately 25,000 children and adults in the EU.

Defining Refractory Rheumatoid Arthritis

Dr. Maya Buch from Leeds has a thoughtful Viewpoint article in Annals of Rheumatic Disease on how to consider and manage the refractory or difficult rheumatoid arthritis (RA) patient.

Despite advances in our understanding the pathogenesis of RA and the advent of novel biologic and small molecule disease-modifying antirheumatic drugs, we still have a regretful proportion of patients who are refractory to our best therapies.

Uveitis in JIA: Screen All, Treat Early

A European group of experts has formulated consensus-based recommendations for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, focusing on screening, monitoring, and treatment of this potentially devastating extra-articular manifestation of JIA.